Opinion
Video
Author(s):
Looking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
SBRT may offer a safe alternative to CFRT after prostatectomy
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic